Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 3, 2015, Pages 256-262

  Jenkin, Kayte A ^a   Mcainch, Andrew J ^a   Zhang, Yuan ^b   Kelly, Darren J ^b   Hryciw, Deanne H ^b  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Albumin; Cannabinoid; Cannabinoid receptor 1; Diabetes; G protein coupled receptor 55; Glucose; Kidney; Proximal tubule

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; DRUG RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MESSENGER RNA; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; ANIMAL; CELL LINE; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84922631037     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12355     Document Type: Article

References (44)

1. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet. Med. 2002; 19: 1-5.
2. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr. Diab. Rep. 2007; 7: 449-53.
3. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004; 66: 1596-605.
4. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999; 56: 393-405.
5. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-80.
6. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int. 2006; 69: 440-9.
7. Imbernon M, Whyte L, Diaz-Arteaga A et al. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors. Mol. Cell. Endocrinol. 2014; 383: 159-69.
8. Moreno-Navarrete JM, Catalan V, Whyte L et al. The L-alpha-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 2012; 61: 281-91.
9. Mushref MA, Srinivasan S. Effect of high fat-diet and obesity on gastrointestinal motility. Ann. Transl. Med. 2013; 1: 14.
10. Rajesh M, Batkai S, Kechrid M et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012; 61: 716-27.
11. Zhang F, Hong S, Stone V, Smith PJ. Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J. Pharmacol. Exp. Ther. 2007; 323: 508-15.
12. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356-67.
13. Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: Structure-activity relationships and potential therapeutic applications. Curr. Top. Med. Chem. 2008; 8: 205-30.
14. Janiak P, Poirier B, Bidouard JP et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 2007; 72: 1345-57.
15. Nam DH, Lee MH, Kim JE et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 2012; 153: 1387-96.
16. Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol. Pain. 2010; 6: 16-38.
17. Dani M, Guindon J, Lambert C, Beaulieu P. The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur. J. Pharmacol. 2007; 573: 214-15.
18. Mukhopadhyay P, Pan H, Rajesh M et al. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 2010; 160: 657-68.
19. Horvath B, Mukhopadhyay P, Hasko G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am. J. Path. 2012; 180: 432-42.
20. Barutta F, Corbelli A, Mastrocola R et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010; 59: 1046-54.
21. Barutta F, Piscitelli F, Pinach S et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011; 60: 2386-96.
22. Jenkin KA, McAinch AJ, Briffa JF et al. Cannabinoid receptor 2 expression in human proximal tubule cells is regulated by albumin independent of ERK1/2 signaling. Cell. Physiol. Biochem. 2013; 32: 1309-19.
23. Simcocks AC, O'Keefe L, Jenkin KA, Mathai ML, Hryciw DH, McAinch AJ. A potential role for GPR55 in the regulation of energy homeostasis. Drug Discov. Today 2013; 19: 1145-51.
24. Sawzdargo M, Nguyen T, Lee DK et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 1999; 64: 193-8.
25. Ryberg E, Larsson N, Sjogren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007; 152: 1092-101.
26. Kargl J, Balenga N, Parzmair GP, Brown AJ, Heinemann A, Waldhoer M. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J. Biol. Chem. 2012; 287: 44234-48.
27. Romero-Zerbo SY, Rafacho A, Diaz-Arteaga A et al. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J. Endocrinol. 2011; 211: 177-85.
28. Jenkin KA, McAinch AJ, Grinfeld E, Hryciw DH. Role for cannabinoid receptors in human proximal tubular hypertrophy. Cell. Physiol. Biochem. 2010; 26: 879-86.
29. Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 2013; 24: 302-8.
30. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab. 2007; 33: 85-95.
31. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011; 300: R1009-22.
32. McKillop AM, Moran BM, Abdel-Wahab YH, Flatt PR. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br. J. Pharmacol. 2013; 170: 978-90.
33. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012; 2012: 146154.
34. Balenga NA, Aflaki E, Kargl J et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 2011; 21: 1452-69.
35. Cable JC, Tan GD, Alexander SP, O'Sullivan SE. The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes. Lipids Health Dis. 2014; 13: 43.
36. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005; 353: 2121-34.
37. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: The study evaluating rimonabant efficacy in drug-naive diabetic patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008; 31: 2169-76.
38. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
39. Sink KS, McLaughlin PJ, Wood JA et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008; 33: 946-55.
40. Son MH, Kim HD, Chae YN et al. Peripherally acting CB1-receptor antagonist: The relative importance of central and peripheral CB1 receptors in adiposity control. Int. J. Obes. 2010; 34: 547-56.
41. Tam J, Cinar R, Liu J et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012; 16: 167-79.
42. McAinch AJ, Steinberg GR, Mollica J et al. Leptin stimulation of COXIV is impaired in obese skeletal muscle myotubes. Obes Res. Clin. Pract. 2007; 1: 1-78.
43. T method. Nat. Protoc. 2008; 3: 1101-8.
44. + exchanger regulatory factor 1 (NHERF1) PDZ scaffold binds an internal binding site in the scavenger receptor megalin. Cell. Physiol. Biochem. 2011; 27: 171-8.